FARMACOCINETICA DELL'EPOSSIDO DELLA CARBAMAZEPINA IN SOGGETTI TRATTATI CON VALPROATO DI SODIO

Translated title of the contribution: Pharmacokinetics of carbamazepine-10,11-epoxide in subjects treated with sodium valproate

F. Pisani, M. Caputo, A. Fazio, G. Oteri, M. Russo, E. Spina, E. Perucca, L. Bertilsson

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

The single oral dose pharmacokinetics of carbamazepine-10,11-epoxide (CBZ-E), the active metabolite of carbamazepine, were studied in six healthy volunteers during a control session and during treatment with sodium valproate at a daily dose of 1000 mg. Sodium valproate increased the CBZ-E half-life from 6.3 ± 1.2 to 9.0 ± 2.0 h (Mean values ± S.D.) and decreased its clearance from 90.6 ± 18.8 to 63.2 ± 16.1 ml h-1 kg-1 (Mean values ± S.D.). These results suggest that sodium valproate impairs the elimination of CBZ-E, presumably by inhibiting its metabolism.

Translated title of the contributionPharmacokinetics of carbamazepine-10,11-epoxide in subjects treated with sodium valproate
Original languageItalian
Title of host publicationBollettino - Lega Italiana contro l'Epilessia
Pages351-352
Number of pages2
Edition66-67
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Pharmacokinetics of carbamazepine-10,11-epoxide in subjects treated with sodium valproate'. Together they form a unique fingerprint.

Cite this